Literature DB >> 20559045

Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc.

Pierre Delobel, Stéphanie Raymond, Maud Mavigner, Michelle Cazabat, Muriel Alvarez, Bruno Marchou, Patrice Massip, Jacques Izopet.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20559045     DOI： 10.1097/QAD.0b013e328338b7a6

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

1.  V1 and V2 Domains of HIV Envelope Contribute to CCR5 Antagonist Resistance.

Authors:  Ellen Wu; Yueqi Du; Xiang Gao; Jie Zhang; John Martin; Makedonka Mitreva; Lee Ratner
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

2.  Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.

Authors:  Athe M N Tsibris; Zixin Hu; Roger Paredes; Kay E Leopold; Opass Putcharoen; Allison L Schure; Natalie Mazur; Eoin Coakley; Zhaohui Su; Roy M Gulick; Daniel R Kuritzkes
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

3.  HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.

Authors:  Opass Putcharoen; Sun Hee Lee; Timothy J Henrich; Zixin Hu; Jakapat Vanichanan; Eoin Coakley; Wayne Greaves; Roy M Gulick; Daniel R Kuritzkes; Athe M N Tsibris
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

4.  Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.

Authors:  Takeo Kuwata; Ikumi Enomoto; Masanori Baba; Shuzo Matsushita
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

5.  A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.

Authors:  Michael Roche; Hamid Salimi; Renee Duncan; Brendan L Wilkinson; Kelechi Chikere; Miranda S Moore; Nicholas E Webb; Helena Zappi; Jasminka Sterjovski; Jacqueline K Flynn; Anne Ellett; Lachlan R Gray; Benhur Lee; Becky Jubb; Mike Westby; Paul A Ramsland; Sharon R Lewin; Richard J Payne; Melissa J Churchill; Paul R Gorry
Journal:  Retrovirology       Date:  2013-04-20       Impact factor: 4.602

6.  V3-independent competitive resistance of a dual-X4 HIV-1 to the CXCR4 inhibitor AMD3100.

Authors:  Yosuke Maeda; Hiromi Terasawa; Yusuke Nakano; Kazuaki Monde; Keisuke Yusa; Shinichi Oka; Masafumi Takiguchi; Shinji Harada
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.